Eprosartan Rx

Select the drug indication to add to your list


Only 4 drugs may be compared at once

Generic Name and Formulations:

Eprosartan (as mesylate) 400mg, 600mg; tabs.

Select therapeutic use:

Indications for Eprosartan:



Monotherapy: not volume depleted: initially 600mg once daily. Usual range: 400–800mg/day given as a single dose or in two divided doses. Moderate-to-severe renal impairment: max 600mg daily.


Not established.


Concomitant aliskiren in patients with diabetes.

Boxed Warning:

Fetal toxicity.


Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before beginning therapy or monitor closely. Monitor BP, renal function, electrolytes. Renal artery stenosis. Severe CHF. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).


See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; avoid. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors; monitor renal function periodically in elderly and/or volume-depleted. May increase lithium levels; monitor.

Adverse Reactions:

Viral infection, injury, fatigue, abdominal pain, hypertriglyceridemia, arthralgia, depression, urinary tract or upper respiratory tract infection, rhinitis, pharyngitis, coughing, hypotension, rhabdomyolysis (rare).


Formerly known under the brand name Teveten.


Hepatic. 98% protein bound.


Biliary, renal.

How Supplied:

Contact supplier